DB
NTLA icon

Dmitry Balyasny’s Intellia Therapeutics NTLA Stock Holding History

Dmitry Balyasny’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-492,100
Closed -$5.74M – 3140
2024
Q4 		$5.74M Buy
+492,100
New +$7.68M 0.01% 1203
2022
Q4 		– Sell
-10,000
Closed -$560K – 3080
2022
Q3 		$560K Buy
+10,000
New +$620K ﹤0.01% 2002

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Dmitry Balyasny's NTLA Position: Q2 2026 in Review

Dmitry Balyasny sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 169,286 shares — an estimated $2.17M sold.

Dmitry Balyasny first reported a position in NTLA in Q4 2018 and held it in 15 quarters. The position peaked at $26.9M in Q4 2024. 327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Dmitry Balyasny reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 169,286 Intellia Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Dmitry Balyasny first reported a position in Intellia Therapeutics in Q4 2018 and held it in 15 quarters.
  • Dmitry Balyasny's Intellia Therapeutics position peaked at $26.9M in Q4 2024.
  • 327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.